Information Provided By:
Fly News Breaks for February 8, 2018
ENTA
Feb 8, 2018 | 07:45 EDT
RBC Capital analyst Brian Abrahams raised his price target on Enanta to $78 after the company's Q1 earnings beat, noting the "high royalties stemming from the Mavyret launch" highlighting Enanta's Hep-C competitive strength. Abrahams keeps his Sector Perform rating, adding that the "potentially de-risking data from '305 in NASH/PBC or '938 in RSV is likely at least a year away".
News For ENTA From the Last 2 Days
There are no results for your query ENTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.